During Friday’s Current trade, Shares of Invesco Mortgage Capital Inc (NYSE:IVR), lost -0.25% to $13.81.
Invesco Mortgage Capital Inc (IVR) declared financial results for the quarter ended June 30, 2015, reporting core earnings* of $0.41 per common share and book value per diluted common share** of $18.62. Second quarter core earnings reflect lower interest income and contribution to earnings from unmerged real estate joint ventures relative to first quarter 2015. Interest income was primarily influenced by faster prepayment speeds, higher amortization, and reinvestment of principal repayments into assets with lower yields.
On August 10, 2015, the Company declared the restatement of its financial statements for the years ended 2013 and 2014 and the quarter ended March 31, 2015. The restatement corrects an error in the U.S. GAAP accounting treatment for credit risk transfer securities issued by government-sponsored enterprises (“GSE CRTs”) and interest-only strips of residential mortgage-backed securities that are guaranteed by a U.S. government agency (“Agency MBS IOs”). We determined that these assets comprise embedded derivatives which should be accounted for under the accounting guidance for derivatives with changes in fair value reflected in the income statement instead of other comprehensive income. Formerly stated key metrics such as economic return, book value per share, core earnings per common share and leverage ratios did not change. The changes also have no impact on our taxable income or compliance with REIT tax requirements.
Invesco Mortgage Capital Inc., a real estate investment trust, focuses on investing in, financing, and managing residential and commercial mortgage-backed securities and mortgage loans. It invests in residential mortgage-backed securities for which a U.S. government agency guarantees payments of principal and interest on the securities; residential mortgage-backed securities that are not issued or guaranteed by a U.S. government agency; commercial mortgage-backed securities; residential and commercial mortgage loans; and other real estate-related financing arrangements.
Shares of Criteo SA (ADR)(NASDAQ:CRTO), inclined 5.20% to $45.94, during its current trading session.
Criteo S.A. (CRTO), the performance marketing technology company, recently declared its financial results for the second quarter ended June 30, 2015.
- Revenue in the second quarter 2015 raised 64% (or 51% at constant currency1) to EURO271 million, contrast with EURO165 million in the second quarter 2014.
- Revenue not taking into account Traffic Acquisition Costs, or Revenue ex-TAC, in the second quarter 2015 grew 65% (or 52% at constant currency) to EURO110 million, contrast with EURO67 million in the second quarter 2014.
- Net income in the second quarter 2015 raised to EURO4 million, contrast with EURO2 million in the second quarter 2014.
- Adjusted EBITDA for the second quarter 2015 was EURO22 million, an enhance of 64% (or 60% at constant currency), contrast with EURO13 million in the second quarter 2014.
- Cash flow from operating activities in the second quarter 2015 was EURO11 million, contrast with EURO11 million in the second quarter 2014.
Criteo S.A., a technology company, engages in the digital performance marketing in France and internationally. The company leverages granular data to engage and convert customers on behalf of its advertiser clients. Its Criteo Engine solution comprises prediction algorithms that predict the probability and nature of a user’s engagement with a given advertisement; and recommendation algorithms that create and tailor advertisements to specific user interest through modifying the advertisement’s creative content and presentation, and determining the specific products and services to comprise in the advertisement.
Motorola Solutions Inc (NYSE:MSI), during its Friday’s current trading session decreased -0.23% to $63.74.
Motorola Solutions (MSI) declared that it has commenced a modified “Dutch Auction” tender offer to repurchase shares of its common stock for an aggregate purchase price of up to $2 billion (subject to a customary enhance if the tender offer is oversubscribed).
Motorola Solutions stockholders may tender all or a portion of their shares (1) at a price specified by the tendering stockholder of not less than $61.00 per share and not more than $66.50 per share or (2) without specifying a purchase price, in which case their shares will be purchased at the purchase price determined in accordance with the tender offer. When the tender offer expires, Motorola Solutions will determine the lowest price within the range of prices specified above that allows it to purchase up to an aggregate of $2 billion of its common stock.
Motorola Solutions, Inc. provides mission-critical communication infrastructure, devices, software, and services in North America, Latin America, the Asia Pacific, the Middle East, Europe, and Africa. The company operates in two segments, Products and Services. The Products segment offers a portfolio of network infrastructure, devices, accessories, and software for government, public safety and first-responder agencies, municipalities, and commercial and industrial customers.
Finally, Hospira, Inc. (NYSE:HSP), decreased -0.02%, to $89.61.
Hospira, Inc. (HSP) has received approval from ANVISA – the National Health Surveillance Agency in Brazil – for Remsima (infliximab), the first biosimilar monoclonal antibody approved for use in Brazil. The medication will be marketed by Hospira. Hospira also markets and sells biosimilar infliximab in 26 European countries and in Canada under the brand name Inflectra. This important product has been approved in Brazil for the treatment of: rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, Crohn’s disease in adults and children, fistulizing Crohn’s disease (advanced), colitis and ulcerative rectocolitis.
Remsima is the first biological medication approved by Brazil’s regulator, ANVISA, based on comparability. A comparability study is required because under ANVISA’s Normative Resolution RDC 55/2010, biosimilarity must be proven by direct comparison with the reference biological drug (products must be contrast in a single clinical trial and using the same procedures). The study offered evidence of similarity between Remsima and the reference biological product, Remicade™ (infliximab).
Hospira, Inc. provides injectable drugs and infusion technologies to develop, manufacture, distribute, and market products worldwide. The company operates through Americas, EMEA, and APAC segments. It provides specialty injectable pharmaceuticals, which comprise about 200 injectable generic drugs in multiple dosages and formulations; and proprietary specialty injectables, such as Precedex, a proprietary drug for sedation.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
